📈 Markets & Finance
Live
Ligand Pharmaceuticals Reaches Analyst Target Price
In recent trading, shares of Ligand Pharmaceuticals Inc (Symbol: LGN) have crossed above the average analyst 12-month target price of $37.39, changing hands for $39.60/share. When a stock reaches the
Nasdaq News — 20 July 2026
Text:
9
0
0
In recent trading, shares of Ligand Pharmaceuticals Inc (Symbol: LGN) have crossed above the average analyst 12-month target price of $37.39, changing
Read Full Story at Nasdaq News → Sources
📈 Markets & Finance
YPF executive buys $200,000 in shares at $46.26
📈 Markets & Finance
Indian Shares Open Flat, Tracking Mixed Global Market Cues
📈 Markets & Finance
The World Cup could make 2026 the 'summer of working from home,' says RTO guru Nicholas Bloom
📈 Markets & Finance
REMX hits rare oversold level at 29.98
📈 Markets & Finance
Stock market today: S&P 500, Nasdaq, Dow futures fall as oil surges, Trump declares ceasefire 'over'
📈 Markets & Finance
Weather Channel raises streaming price to $5 a month
